Tirzepatide weight loss on the NHS: your real options explained

What the NHS criteria look like right now, and where they're heading

NICE's appraisal of tirzepatide (TA1026) set out a phased rollout rather than open access. The first cohort, active from June 2025, requires a BMI of 40 or above and four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That's a deliberately narrow gate. Most adults living with obesity, even those who've tried other treatments, don't meet all four conditions simultaneously.

The second cohort opened in June 2026: BMI 35–39.9 with four or more of the same conditions. A third cohort, covering BMI 40-plus with three conditions, is expected around March 2027. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance applies BMI thresholds 2.5 kg/m² lower throughout. You can check the NHS Mounjaro eligibility detail for a fuller breakdown of each cohort and what the conditions list actually covers.

From April 2026, some GP practices can prescribe tirzepatide under the updated GP contract, but participation is optional and patchy. Meeting the criteria on paper doesn't guarantee your practice is participating, or that supply is immediately available. The NICE TA1026 recommendations chapter sets out the clinical criteria in full if you'd like to read them directly.

What private prescribing actually offers, and what it doesn't

Private prescribing sits alongside the NHS pathway, not above it. The licensed eligibility criteria are different: adults with a BMI of 30 or above, or 27-plus with at least one weight-related condition such as prediabetes, hypertension, high cholesterol, or obstructive sleep apnoea. That's a broader population than the NHS cohorts currently cover, which is why many people look at private routes first.

What private prescribing cannot do is skip the clinical assessment. A prescriber still reviews your health, your medications, your history, and whether tirzepatide is appropriate for you. At a regulated pharmacy that assessment is real, photo-ID and live weight verification are part of the process, not optional extras. You can check any online pharmacy against the GPhC register in about thirty seconds: search the pharmacy's name or registration number at pharmacyregulation.org/registers and the entry should appear immediately. If it doesn't, that's your answer.

Cost is a genuine factor on the private route, and the landscape changed significantly after Eli Lilly raised list prices from September 2025. Typical private prices now range roughly £149–£375 per month depending on dose and provider, as widely reported at the time. The Mounjaro cost context page gives a fuller picture of what those prices do and don't include. A transparent private service covers the consultation, prescription, and delivery in one figure, no separate fees added at checkout.

The decision most people are actually weighing

In practice, the choice between NHS and private access usually comes down to three things: do you meet the current NHS criteria, does your GP practice participate, and how long are you prepared to wait? If the answer to all three points in the NHS direction, the NHS route is worth pursuing. If your BMI is below 40, your conditions list is shorter than four, or your practice isn't yet signed up, private prescribing may be the more realistic path right now.

What both routes share is that neither will hand over tirzepatide without a clinical assessment. The Mounjaro NHS jab page has more detail on how the NHS dispensing process actually works for people who do qualify. For those considering private prescribing, how to access tirzepatide privately in the UK sets out what a responsible process looks like step by step, and where to buy tirzepatide for weight loss covers the safety checks worth doing before committing to any provider.

One safety consideration worth stating plainly

The market for tirzepatide pens outside of licensed pharmacies has a serious counterfeit problem. The MHRA has issued multiple public warnings (including a raid on an illicit manufacturing site producing fake tirzepatide pens in the UK in October 2025) and any supply offered without a formal prescription process should be treated as suspect. The MHRA Yellow Card scheme is the place to report a suspect seller if you encounter one.

Treatment through a regulated service also means clinical support continues after you start. Dose increases are reviewed, not automatic. If a question comes up between orders, the prescribing team is reachable. That aftercare structure matters more than it might sound, tirzepatide is typically taken for months, and circumstances change. If you'd like to understand what the full private treatment process looks like at nume, the about us page explains our clinical setup, and our clinical team is named and verifiable. When you're ready, you can start a free consultation and a GPhC-registered prescriber will review your case the same day.